Prognostic Value of Neurometabolic Networks in CRC (PVNM-CRC)
NCT ID: NCT06930586
Last Updated: 2025-04-30
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
213 participants
Study Classification
OBSERVATIONAL
Study Start Date
2024-03-01
Study Completion Date
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Colorectal cancer (CRC), with annually increasing incidence and mortality worldwide, has become the second leading cause of cancer-related death. The development of CRC often follows the canonical normal-adenoma-carcinoma (N-A-C) sequence driven by progressive accumulation of molecular genetic events, highlighting the importance of early detection and removal of precancerous lesions. However, some patients who have had adenomas removed still have a high risk of developing new adenomas or CRC, especially for those with chronic or systemic disease, indicating that a compositive regulatory network is involved in the tumorigenesis of CRC. Additionally, despite advances in therapeutic strategies having improved the prognosis of CRC patients, tumor metastasis continues to be the predominant cause of mortality. These suggest the need to transcend limitations focusing solely on intertumoral microenvironment or single-timepoint event but adopt a more systemic perspective to elucidate the mechanisms underlying the whole sequence of CRC development and progression.
The gastrointestinal (GI) tract comprises a complex ecosystem with extensive interactions between normal or neoplastic epithelial cells with immune, neuronal, and other cell types, as well as microorganisms and metabolites within the gut lumen. Specifically, the intricate relationship between the GI tract and the central nervous system (CNS), collectively known as the brain-gut axis, plays a pivotal role in the pathogenesis of gastrointestinal disorders and neoplasm. For instance, chronic stress increased the risk of colon cancer via activating the COX-2/PEG2 system and promoted tumor cell dissemination by remodeling lymph vasculature. The bidirectional communications of the brain-gut axis are generally found to be mediated by neurotransmitters, inflammatory cytokines, metabolites, or gut microbiota. Nonetheless, the spotlight has shone primarily on the brain-gut crosstalk mechanisms in experimental cellular or animal models, with less attention paid to the structural and functional alterations on the brain networks at the patient level.
The evolution of functional neuroimaging modalities and neuroscience technologies has enabled accurate delineation of CNS activities. Specifically, nuclear medicine imaging technology using 2-18F fluoro-2-deoxy-D-glucose (18F-FDG) to adopt whole-body imaging information, is the optimal in vivo method for the investigation of regional human brain metabolism and associations with systemic disorders. We have previously identified the neuronal metabolic-ventricular dyssynchronization axis which might related to major arrhythmic events using myocardial perfusion imaging and the brain 18F-FDG positron emission tomography (PET). Given the potential dual interactions of the brain-gut axis, identification of specific brain regions associated with CRC development and progression might lead to a better understanding of the disease's neurobiological underpinnings and inform the development of targeted therapeutic strategies.
Hence, this study was structured to elucidate the role of neuro-metabolism and its potential mediator in regulating CRC tumorigenesis and metastasis. By delving into the neurometabolic-gut axis in CRC, the resulting mechanistic insights might be leveraged to identify diagnostic and prognostic biomarkers and to develop novel therapeutic interventions for CRC patients.
The gastrointestinal (GI) tract comprises a complex ecosystem with extensive interactions between normal or neoplastic epithelial cells with immune, neuronal, and other cell types, as well as microorganisms and metabolites within the gut lumen. Specifically, the intricate relationship between the GI tract and the central nervous system (CNS), collectively known as the brain-gut axis, plays a pivotal role in the pathogenesis of gastrointestinal disorders and neoplasm. For instance, chronic stress increased the risk of colon cancer via activating the COX-2/PEG2 system and promoted tumor cell dissemination by remodeling lymph vasculature. The bidirectional communications of the brain-gut axis are generally found to be mediated by neurotransmitters, inflammatory cytokines, metabolites, or gut microbiota. Nonetheless, the spotlight has shone primarily on the brain-gut crosstalk mechanisms in experimental cellular or animal models, with less attention paid to the structural and functional alterations on the brain networks at the patient level.
The evolution of functional neuroimaging modalities and neuroscience technologies has enabled accurate delineation of CNS activities. Specifically, nuclear medicine imaging technology using 2-18F fluoro-2-deoxy-D-glucose (18F-FDG) to adopt whole-body imaging information, is the optimal in vivo method for the investigation of regional human brain metabolism and associations with systemic disorders. We have previously identified the neuronal metabolic-ventricular dyssynchronization axis which might related to major arrhythmic events using myocardial perfusion imaging and the brain 18F-FDG positron emission tomography (PET). Given the potential dual interactions of the brain-gut axis, identification of specific brain regions associated with CRC development and progression might lead to a better understanding of the disease's neurobiological underpinnings and inform the development of targeted therapeutic strategies.
Hence, this study was structured to elucidate the role of neuro-metabolism and its potential mediator in regulating CRC tumorigenesis and metastasis. By delving into the neurometabolic-gut axis in CRC, the resulting mechanistic insights might be leveraged to identify diagnostic and prognostic biomarkers and to develop novel therapeutic interventions for CRC patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multi-Reader Multi-Case Trial Evaluating Computer-Aided Tool for Prognostic Prediction of Colorectal Liver Metastases
NCT07027605
Colorectal Liver Metastasis (CRLM)
RECRUITING
Detecting Colorectal Cancer With Liver Metastatic Lesions Using Novel Precise Imaging Tools
NCT06935149
Liver Metastasis Colon Cancer
NOT_YET_RECRUITING
PHASE1
Role of MRI in the Evaluation of Hepatic Metastases of Colorectal Cancer
NCT05950503
Colorectal Cancer
RECRUITING
Radiomics of Colorectal Liver Metastases: Identification of New Prognostic Biomarkers.
NCT06779734
Liver Metastases from Colorectal Cancer (mCRC)
COMPLETED
Time to Surgery and Survival Outcomes for Patients With Resected Colorectal Carcinoma: Multicenter Study (BIG RENAPE)
NCT04916054
Colo-rectal Cancer
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OBJECTIVE(S) \& HYPOTHESIS(ES) Objective: Evaluate area under curve (AUC) of BRIDGE in predicting overall survival (OS) for CRC patients. Compare the AUC of BRIDGE with clinical prediction models in predicting survival status for CRC patients. Evaluate the sensitivity, specificity, positive prediction value (PPV) and negative prediction value (NPV)of BRIDGE in predicting OS for CRC patients.
Hypothesis: BRIDGE achieves an AUC over 0.80 in predicting OS for CRC patients. BRIDGE is superior to clinical prediction models in terms of AUC in predicting OS for CRC patients.
BACKGROUND \& RATIONALE Colorectal cancer (CRC), with annually increasing incidence and mortality worldwide, has become the second leading cause of cancer-related death. The gastrointestinal (GI) tract comprises a complex ecosystem with extensive interactions between normal or neoplastic epithelial cells with immune, neuronal, and other cell types, as well as microorganisms and metabolites within the gut lumen. Specifically, the intricate relationship between the GI tract and the central nervous system (CNS), collectively known as the brain-gut axis, plays a pivotal role in the pathogenesis of gastrointestinal disorders and neoplasm. For instance, chronic stress increased the risk of colon cancer via activating the COX-2/PEG2 system and promoted tumor cell dissemination by remodeling lymph vasculature. The bidirectional communications of the brain-gut axis are generally found to be mediated by neurotransmitters, inflammatory cytokines, metabolites, or gut microbiota. Nonetheless, the spotlight has shone primarily on the brain-gut crosstalk mechanisms in experimental cellular or animal models, with less attention paid to the structural and functional alterations on the brain networks at the patient level.
The evolution of functional neuroimaging modalities and neuroscience technologies has enabled accurate delineation of CNS activities. Specifically, nuclear medicine imaging technology using 2-18F fluoro-2-deoxy-D-glucose (18F-FDG) to adopt whole-body imaging information, is the optimal in vivo method for the investigation of regional human brain metabolism and associations with systemic disorders. The investigators have previously identified the neuronal metabolic-ventricular dyssynchronization axis which might related to major arrhythmic events using myocardial perfusion imaging and the brain 18F-FDG positron emission tomography (PET). Given the potential dual interactions of the brain-gut axis, identification of specific brain regions associated with CRC development and progression might lead to a better understanding of the disease's neurobiological underpinnings and inform the development of targeted therapeutic strategies. Hence, this study was structured to elucidate the role of neuro-metabolism and its potential mediator in regulating CRC tumorigenesis and metastasis. By delving into the neurometabolic-gut axis in CRC, the resulting mechanistic insights might be leveraged to identify diagnostic and prognostic biomarkers and to develop novel therapeutic interventions for CRC patients.
Previously, investigators have constructed a BRIDGE based on retrospective datasets. The study is conducted to further prospectively verify the clinical applicability and generalizability of BRIDGE in predicting OS for CRC patients. The prediction performance of BRIDGE will be evaluated in a prospective dataset, and compared to conventional clinical-based prediction models in the trial, which might potentially provide important evidence for the feasibility and clinical value of integration of brain images for artificial intelligence-aided GI cancer medicine.
The primary accuracy endpoint in the study is the AUC, a significant indicator of classification performance of a binary classifier, which has been widely used to evaluate model performance in the field of machine learning.
METHODOLOGY Inclusion Criteria
1\. Age ≥ 18 years. 2. Have pathologically confirmed as colorectal adenocarcinoma. 3. Have been diagnosed as colorectal cancer (CRC) by PET/CT. 4. Images of PET/CT sequences are available. Exclusion Criteria
1. Has a concomitant additional malignancy that is processing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
2. Have a history of cerebrovascular disease (CVD), refers to a general term for a class of diseases in which cerebrovascular lesions lead to brain dysfunction, including cerebrovascular stenosis, brain localized or diffuse brain dysfunction caused by various cerebrovascular lesions such as vascular occlusion, cerebrovascular rupture, cerebrovascular malformations, or cerebrovascular injuries in doctoral dissertations of Capital Medical University, mainly including ischemic stroke and hemorrhagic stroke, defined as cerebrovascular diseases caused by organic brain injury with sudden onset, rapid onset of localized or diffuse brain function defects as clinical features.
Have a major neuropsychiatric abnormality, or had a life expectancy of fewer than 3 months.
3. Have a history of mental illness, including but not limited to parkinsonism, depression, anxiety, schizophrenia, or dementia.
4. Have a history of severe head trauma.
5. Have a history or current evidence of any condition, laboratory abnormality, or substance abuse disorders that might confound the results of trial or interfere with the subject's participation for the full duration of the trial.
6. Have a history of acute cardiovascular events within 4 weeks before enrollment, including but not limited to acute coronary syndrome, acute decompensated heart failure, and malignant arrhythmia; have a non-tumor condition limiting life expectancy to less than 1 year.
7. Have an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (i.e., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
8. Have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to treatment initiation.
9. Have an active infection requiring systemic therapy.
10. Be pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial.
11. Lack of images of PET/CT, or insufficient quality of PET/CT images to obtain measurements.
12. Be currently participating in an additional trial and receiving study therapy. Subject Withdrawal/Discontinuation Criteria The subject discontinues/withdraws study during the trial. Basic Information Collection and Serial Number Generation Once enrollment, the basic information including demographics and baseline clinical characteristics of each subject will be recorded. A unique tracking number will be generated randomly for each subject that will be used to identify the subject for all procedures in the trial.
Imaging Data Collection and Process PET/CT Imaging Collection and Anonymization For each subject, initial tumor imaging by PET/CT should have been performed within 1-2 weeks after enrolled. The process for imaging collection and transmission is manipulated in a uniform imaging protocol by radiologists and technicians in participating institutions. The whole series of PET/CT scans should be exported as DICOM files and completely anonymized with unique tracking number before uploaded to the designated cloud platform.
PET/CT Imaging Quality Control Images of PET/CT scans acquired in sites will be downloaded and reviewed by an independent radiologist experienced in PET/CT in the central laboratory to ensure high image quality
Hypothesis: BRIDGE achieves an AUC over 0.80 in predicting OS for CRC patients. BRIDGE is superior to clinical prediction models in terms of AUC in predicting OS for CRC patients.
BACKGROUND \& RATIONALE Colorectal cancer (CRC), with annually increasing incidence and mortality worldwide, has become the second leading cause of cancer-related death. The gastrointestinal (GI) tract comprises a complex ecosystem with extensive interactions between normal or neoplastic epithelial cells with immune, neuronal, and other cell types, as well as microorganisms and metabolites within the gut lumen. Specifically, the intricate relationship between the GI tract and the central nervous system (CNS), collectively known as the brain-gut axis, plays a pivotal role in the pathogenesis of gastrointestinal disorders and neoplasm. For instance, chronic stress increased the risk of colon cancer via activating the COX-2/PEG2 system and promoted tumor cell dissemination by remodeling lymph vasculature. The bidirectional communications of the brain-gut axis are generally found to be mediated by neurotransmitters, inflammatory cytokines, metabolites, or gut microbiota. Nonetheless, the spotlight has shone primarily on the brain-gut crosstalk mechanisms in experimental cellular or animal models, with less attention paid to the structural and functional alterations on the brain networks at the patient level.
The evolution of functional neuroimaging modalities and neuroscience technologies has enabled accurate delineation of CNS activities. Specifically, nuclear medicine imaging technology using 2-18F fluoro-2-deoxy-D-glucose (18F-FDG) to adopt whole-body imaging information, is the optimal in vivo method for the investigation of regional human brain metabolism and associations with systemic disorders. The investigators have previously identified the neuronal metabolic-ventricular dyssynchronization axis which might related to major arrhythmic events using myocardial perfusion imaging and the brain 18F-FDG positron emission tomography (PET). Given the potential dual interactions of the brain-gut axis, identification of specific brain regions associated with CRC development and progression might lead to a better understanding of the disease's neurobiological underpinnings and inform the development of targeted therapeutic strategies. Hence, this study was structured to elucidate the role of neuro-metabolism and its potential mediator in regulating CRC tumorigenesis and metastasis. By delving into the neurometabolic-gut axis in CRC, the resulting mechanistic insights might be leveraged to identify diagnostic and prognostic biomarkers and to develop novel therapeutic interventions for CRC patients.
Previously, investigators have constructed a BRIDGE based on retrospective datasets. The study is conducted to further prospectively verify the clinical applicability and generalizability of BRIDGE in predicting OS for CRC patients. The prediction performance of BRIDGE will be evaluated in a prospective dataset, and compared to conventional clinical-based prediction models in the trial, which might potentially provide important evidence for the feasibility and clinical value of integration of brain images for artificial intelligence-aided GI cancer medicine.
The primary accuracy endpoint in the study is the AUC, a significant indicator of classification performance of a binary classifier, which has been widely used to evaluate model performance in the field of machine learning.
METHODOLOGY Inclusion Criteria
1\. Age ≥ 18 years. 2. Have pathologically confirmed as colorectal adenocarcinoma. 3. Have been diagnosed as colorectal cancer (CRC) by PET/CT. 4. Images of PET/CT sequences are available. Exclusion Criteria
1. Has a concomitant additional malignancy that is processing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
2. Have a history of cerebrovascular disease (CVD), refers to a general term for a class of diseases in which cerebrovascular lesions lead to brain dysfunction, including cerebrovascular stenosis, brain localized or diffuse brain dysfunction caused by various cerebrovascular lesions such as vascular occlusion, cerebrovascular rupture, cerebrovascular malformations, or cerebrovascular injuries in doctoral dissertations of Capital Medical University, mainly including ischemic stroke and hemorrhagic stroke, defined as cerebrovascular diseases caused by organic brain injury with sudden onset, rapid onset of localized or diffuse brain function defects as clinical features.
Have a major neuropsychiatric abnormality, or had a life expectancy of fewer than 3 months.
3. Have a history of mental illness, including but not limited to parkinsonism, depression, anxiety, schizophrenia, or dementia.
4. Have a history of severe head trauma.
5. Have a history or current evidence of any condition, laboratory abnormality, or substance abuse disorders that might confound the results of trial or interfere with the subject's participation for the full duration of the trial.
6. Have a history of acute cardiovascular events within 4 weeks before enrollment, including but not limited to acute coronary syndrome, acute decompensated heart failure, and malignant arrhythmia; have a non-tumor condition limiting life expectancy to less than 1 year.
7. Have an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (i.e., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
8. Have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to treatment initiation.
9. Have an active infection requiring systemic therapy.
10. Be pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial.
11. Lack of images of PET/CT, or insufficient quality of PET/CT images to obtain measurements.
12. Be currently participating in an additional trial and receiving study therapy. Subject Withdrawal/Discontinuation Criteria The subject discontinues/withdraws study during the trial. Basic Information Collection and Serial Number Generation Once enrollment, the basic information including demographics and baseline clinical characteristics of each subject will be recorded. A unique tracking number will be generated randomly for each subject that will be used to identify the subject for all procedures in the trial.
Imaging Data Collection and Process PET/CT Imaging Collection and Anonymization For each subject, initial tumor imaging by PET/CT should have been performed within 1-2 weeks after enrolled. The process for imaging collection and transmission is manipulated in a uniform imaging protocol by radiologists and technicians in participating institutions. The whole series of PET/CT scans should be exported as DICOM files and completely anonymized with unique tracking number before uploaded to the designated cloud platform.
PET/CT Imaging Quality Control Images of PET/CT scans acquired in sites will be downloaded and reviewed by an independent radiologist experienced in PET/CT in the central laboratory to ensure high image quality
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cancer
Brain Injury
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Colorectal Cancer
1. Entry Criteria Male/Female subjects with rectal cancer of at least 18 years of age will be enrolled in this trial.
2. Subject Inclusion Criteria
In order to be eligible for participation in this trial, the subject must:
1. Be ≥ 18 years of age on day of enrollment.
2. Have pathologically confirmed as rectal adenocarcinoma by electronic colonoscopy biopsy.
3. Have been diagnosed as colorectal cancer (CRC) by enhanced PET/CT.
4. Images of PET/CT sequences are available.
5. Be willing and able to provide written informed assent for Collection and Application of Clinical Sample and Medical Data certified and approved by local ethics committee. Requirements of informed consent for the trial is waived.
6. . Demonstrate adequate organ function as defined.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Male/Female subjects with rectal cancer of at least 18 years of age will be enrolled in this trial.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital of Zhengzhou University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
yujie bai
MD
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
PET/CT
Henan, Henan, China
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
China
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Schledwitz A, Xie G, Raufman JP. Exploiting unique features of the gut-brain interface to combat gastrointestinal cancer. J Clin Invest. 2021 May 17;131(10):e143776. doi: 10.1172/JCI143776.
Reference Type
BACKGROUND
Leslie A, Carey FA, Pratt NR, Steele RJ. The colorectal adenoma-carcinoma sequence. Br J Surg. 2002 Jul;89(7):845-60. doi: 10.1046/j.1365-2168.2002.02120.x.
Reference Type
BACKGROUND
Murphy CC, Zaki TA. Changing epidemiology of colorectal cancer - birth cohort effects and emerging risk factors. Nat Rev Gastroenterol Hepatol. 2024 Jan;21(1):25-34. doi: 10.1038/s41575-023-00841-9. Epub 2023 Sep 18.
Reference Type
BACKGROUND
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024M752975
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
ybai
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases
NCT06404593
COMPLETED
Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine Tumors
NCT06143605
COMPLETED
Liver MRI for Colorectal Cancer Liver Metastasis: Comparative Effectiveness Research for the Choice of Contrast Agents
NCT02652663
UNKNOWN
Study on the No.253 Lymph Node Metastasis Patterns in Left-Sided Colon and Rectal Cancer
NCT06135571
RECRUITING
A Metabolomics-based Study to Explore the Mechanism of Remission of Metabolic Syndrome Radical Resection of Colorectal Cancer
NCT06710314
ENROLLING_BY_INVITATION
Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
NCT01834014
COMPLETED
NA
Mutational Profiling in Colorectal Tumors to Determine Its Role in the Diagnosis, Prognostic Significance and Their Impact in Clinical Management
NCT01371942
UNKNOWN
Integrative Analysis of CRC Liver Metastasis
NCT02917707
RECRUITING
Significance of Benign Lymph Node Enlargement in Colorectal Cancer
NCT06410729
COMPLETED
Colorectal Cancer With Liver-limited Synchronous Metastases: an Inception Cohort Study of Standardised Care Pathways
NCT02456285
COMPLETED
Blood Clearance Kinetics of the Nucleosome and CTCF in Peritoneal Metastasis Colorectal Cancer.
NCT06929013
NOT_YET_RECRUITING
NA
Mesogastrium Metastasis in Colon Cancer
NCT04980287
RECRUITING
Preoperative Inflammatory Markers Predict Postoperative Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Colorectal Carcinomatosis
NCT06318793
COMPLETED
Metastatic Lymph Node Distribution in the Ileum Mesentery of Cecal and Proximal Ascending Colon Cancer
NCT07149623
NOT_YET_RECRUITING
Second Look Laparoscopy in Colorectal Cancer
NCT01628211
UNKNOWN
PHASE2
Immunophenotyping of Metastases From Colorectal Cancer
NCT03604926
COMPLETED
Microwave Ablation Combined With Chemotherapy for Colorectal Liver Metastases： a Multicenter Cohort Study
NCT04562727
NOT_YET_RECRUITING
NA
Distribution and Analysis of Metastatic Lymph Nodes in Colorectal Cancer Patients (DIAMOND)
NCT07306390
NOT_YET_RECRUITING
Study of Immune Response and Liver Damage Induced by Chemotherapy for Liver Metastases of Colorectal Cancer
NCT01673607
UNKNOWN
PHASE2
The China Laparoscopic Right Hemicolectomy SNAPSHOT
NCT04628182
UNKNOWN
To Identify KRAS Gene and Safe Margin in Association With Outcome in Colorectal Liver Metastases Following Ultrasound-guided Radiofrequency Ablation
NCT04417010
UNKNOWN
Role of Photon Counting CT in Detecting Liver Metastatis From Colorectal Cancer
NCT06753903
RECRUITING
Expression of DMBT1 in Colorectal Cancer Patients
NCT02901600
COMPLETED
Observational Study on Treatment of Metastatic Colorectal Cancer and the Role of K-Ras
NCT01651013
UNKNOWN
Clinical Evaluation of PET-CT for Staging of Colorectal Lung Metastases
NCT02942901
COMPLETED